At the early phase of anti-angiogenic treatments, experimental evidence indicates a transient "normalisation" of the tumor vasculature, with a transient increase in tumor perfusion (1). This could provide enhancement of drugs delivery into the tumor. The aim of this work was to study how administration schedule affects potentiation of the chemotherapy drug cyclophosphamide by the anti-angiogenic agent thalidomide. To determine when transient normalization occurs in response to thalidomide, we used EPR oximetry. We previously showed that such measurements provide a surrogate marker for determining the reoxygenation associated with the increase in perfusion during the normalization produced by thalidomide (2). The tumor was treated with cyclophosphamide during this initial normalization period, then tumor regrowth delays were measured. Finally, we determined the penetration of the metabolite of cyclophosphamide (hydroxycyclophosphamide, or OH-CP) into tumors by liquid chromatography coupled with tandem mass spectrometry (HPLS-MS/MS).

